-
HETEROGENEOUS RESPONSES TO BRAZIL’S PHARMACEUTICAL PRICE CAP REGULATION: EVIDENCE FROM PRIVATE INSURANCES AND THE UNIFIED HEALTH SYSTEM
Feb 25, 2026, 14:42 PM -
REAL-WORLD MULTIPLE MYELOMA TREATMENT RESPONSES: EVALUATION OF FRONTLINE REGIMENS IN MELDTM LINKED MEDICARE, LABORATORY AND ELECTRONIC MEDICAL RECORDS...
Feb 25, 2026, 14:42 PM -
PSYCHIATRIC MORBIDITY AMONG INDIVIDUALS WITH INHERITED RETINAL DISEASE- A NATIONWIDE SWEDISH RETROSPECTIVE COHORT STUDY
Feb 25, 2026, 14:42 PM -
EVALUATING MODEL PERFORMANCE FOR BETWEEN-COUNTRY SURVIVAL TRANSPORTABILITY
Feb 25, 2026, 14:42 PM -
OBSERVED CARDIOVASCULAR DISEASE PREVALENCE AMONG OBESE AND TYPE 2 DIABETES PATIENTS WITH AND WITHOUT GLP-1 TREATMENT
Feb 25, 2026, 14:42 PM -
WHAT HEOR CAN LEARN FROM MATURE AI INDUSTRIES AND WHERE THE ANALOGIES BREAK DOWN
Feb 25, 2026, 14:42 PM -
ACCELERATING HEALTH ECONOMIC MODEL CONCEPTUALIZATION USING MULTI-AGENTIC GENERATIVE AI SYSTEMS
Feb 25, 2026, 14:42 PM -
HEALTHCARE COST ASSOCIATED WITH CARDIOVASCULAR-KIDNEY-METABOLIC (CKM) SYNDROME STAGES AMONG ADULTS IN THE UNITED STATES: ANALYSIS OF NATIONALLY REPRESENTATIVE DATA
Feb 25, 2026, 14:42 PM -
THE EXTENT OF TREATMENT RESPONSE AND PREFERENCE HETEROGENEITY IN MAJOR DEPRESSIVE DISORDER: IMPLICATIONS FOR POPULATION-LEVEL RESOURCE ALLOCATION
Feb 25, 2026, 14:42 PM -
THE ECONOMIC COST OF PREVENTABLE BLINDNESS: PROJECTING THE SOCIOECONOMIC BURDEN OF DIABETIC MACULAR EDEMA IN CHILE (2017-2032)
Feb 25, 2026, 14:42 PM -
COST-EFFECTIVENESS OF A NOVEL THERAPY TO PREVENT ADVANCED FRAILTY AMONG PEOPLE WITH HIV
Feb 25, 2026, 14:42 PM -
ONE GLOBAL EVIDENCE PLAN FOR MANY DECISION-MAKERS: ALIGNING EVIDENCE FOR EU JCA, AMCP DOSSIER, AND ICER REVIEWS
Feb 25, 2026, 14:42 PM -
AN AUTOMATED FEASIBILITY ASSESSMENT TOOL FOR INDIRECT TREATMENT COMPARISONS ACROSS MULTIPLE ANALYTICAL METHODS
Feb 25, 2026, 14:42 PM -
COST OF HEALTHCARE IN PATIENTS NEWLY DIAGNOSED WITH NON-CYSTIC FIBROSIS BRONCHIECTASIS
Feb 25, 2026, 14:42 PM -
ECONOMIC EVALUATION OF HARTC 2.0 TRIAL: PREHOSPITAL ACS TRIAGE USING A MODIFIED HEART SCORE WITH POINT-OF-CARE HS-CTNI
Feb 25, 2026, 14:42 PM -
REVIEW OF CEESP ICERS FOR ORPHAN AND NON-ORPHAN TREATMENTS IN FRANCE, 2024 - 2025
Feb 25, 2026, 14:42 PM -
CUSTOMIZATION OF A LARGE LANGUAGE MODEL APPROACH TO CAPTURE PSA AND IMAGING DERIVED REAL-WORLD PROGRESSION EVENTS IN PROSTATE CANCER
Feb 25, 2026, 14:42 PM -
ESTIMATING THE COST OF ORPHAN DRUG TREATMENT FROM THE PERSPECTIVE OF MEXICO'S PUBLIC SECTOR
Feb 25, 2026, 14:42 PM -
SOCIAL DETERMINANTS OF HEALTH ENABLE EARLY IDENTIFICATION OF PREMATURE MORTALITY RISK
Feb 25, 2026, 14:42 PM -
ACCOUNTING FOR RISK-AVERSION IN HEALTH TECHNOLOGY ASSESSMENT: UTILITY ESTIMATION ACROSS MULTIPLE HEALTH INDEXES IN NON-SMALL CELL LUNG CANCER
Feb 25, 2026, 14:42 PM
